On Oct 30, major Wall Street analysts update their ratings for $Inari Medical (NARI.US)$, with price targets ranging from $50 to $74.
Morgan Stanley analyst Kallum Titchmarsh maintains with a buy rating, and maintains the target price at $60.
BofA Securities analyst Travis Steed maintains with a buy rating, and maintains the target price at $68.
Needham analyst Michael Matson maintains with a hold rating.
Stifel analyst Mathew Blackman maintains with a hold rating, and maintains the target price at $50.
Piper Sandler analyst Adam Maeder maintains with a hold rating, and adjusts the target price from $50 to $52.
Furthermore, according to the comprehensive report, the opinions of $Inari Medical (NARI.US)$'s main analysts recently are as follows:
The estimation is that Inari Medical has achieved mid-to-high-teens growth in the US VTE market, indicating that the company may be maintaining market share more effectively than some anticipated. The perspective is that there is room for a more sustained expansion in valuation multiples as skeptical positions appear to have diminishing validity.
Here are the latest investment ratings and price targets for $Inari Medical (NARI.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
